No Data
China Accepts Hengrui Medicine Unit's Marketing Application for Cancer Drug
Jiangsu Hengrui Pharmaceuticals (600276.SH): The application for marketing authorization of Rucanezumab for injection has been accepted.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Suzhou Shengdiya Biomedical Co., Ltd., has received the "Acceptance Notice" issued by the National Medical Products Administration for the marketing authorization application of its pharmaceutical product, Injection of Ruirang Qutuozhudankan (SHR-A1811). The application has been accepted by the National Medical Products Administration and the product has recently been included in the priority review process. Injection of SHR-A1811 can bind and internalize with tumor cells expressing HER2, release toxins through proteinase cleavage in tumor cell lysosomes, induce cell cycle arrest, and induce tumor cell apoptosis.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Hengrui Medicine Gets China Nod for Anti-Hair Loss Drug
GTJA: Medical sector faces growth pressure in the first half of 2024, but the in-hospital market is expected to gradually recover.
The commercialization of innovative drugs continued to maintain high growth in the second quarter, and essential categories such as pharmaceutical opioids and some branded traditional Chinese medicine OTC also maintained a stable growth rate.
Jiangsu Hengrui Pharmaceuticals (600276.SH): Cumulative repurchase of 2.58 million shares.
On September 2nd, Gehuanhui announced that as of August 31, 2024, Jiangsu Hengrui Pharmaceuticals (600276.SH) has accumulated a repurchase of 2,583,204 shares through centralized auction trading, accounting for 0.04% of the company's total share capital. The highest price traded was 40.77 yuan/share, and the lowest price was 39.00 yuan/share. The total amount paid was 102,883,400.00 yuan (excluding transaction costs).
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years AgoNo Data
No Data
